3-Aza-bicyclo[3.2.0]heptane-3-carbonyl chloride | 623580-00-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-Aza-bicyclo[3.2.0]heptane-3-carbonyl chloride
• 英文别名: 3-Azabicyclo[3.2.0]heptane-3-carbonyl chloride
• CAS: 623580-00-7
• 化学式: C₇H₁₀ClNO
• 分子量: 159.615
• InChiKey: XBGXAONDHMFSCO-UHFFFAOYSA-N

物化性质

• 沸点：
  262.3±7.0 °C(Predicted)
• 密度：
  1.303±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-Aza-bicyclo[3.2.0]heptane-3-carbonyl chloride 、 青霉素 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.17h， 生成 3-Aza-bicyclo[3.2.0]heptane-3-carboxylic acid 9-((S)-1-hydroxy-3-methyl-butyl)-8-methoxy-3-methyl-7-oxo-5H,7H-6,12-dioxa-dibenzo[a,d]cycloocten-1-yl ester
  参考文献：
  名称：

  Dibenzodioxocinones—A new class of CETP inhibitors

  摘要：

  Derivatives of the natural product 11-hydroxy-3-[(S)-1-hydroxy-3-methylbutyl]-4-methoxy-9-methyl-5H,7H-dibenzo[b,g][1,5]dioxocin-5-one 1 were studied as novel CETP inhibitors. Compound 2 was identified from HTS as a micromolar inhibitor. The compound suffered from very low stability in plasma. Optimisation by partial synthesis started from 1 and led to low-nanomolar inhibitors with good stability in rat plasma. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.073

文献信息

• [EN] 7-AMINOIMIDAZOTRIAZONES<br/>[FR] 7-AMINOIMIDAZOTRIAZONES
  申请人：BAYER AG

  公开号：WO2003093268A1

  公开（公告）日：2003-11-13

  The invention relates to novel 7-amino-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.

  这项发明涉及新颖的7-氨基咪唑三嗪酮类化合物，以及它们的制备方法和在药物中的应用，特别是用于治疗和/或预防炎症过程和/或免疫性疾病。
• 7-Aminoimidazotriazones
  申请人：Alonso-Alija Cristina

  公开号：US20060040941A1

  公开（公告）日：2006-02-23

  The invention relates to novel 7-amino-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.

  本发明涉及一种新型7-氨基咪唑三唑酮，其制备方法及其在药物中的用途，特别是用于治疗和/或预防炎症过程和/或免疫性疾病。
• 7H-dibenzo[b,g][1,5]dioxocin-5-one derivatives and use thereof
  申请人：Bischoff Hilmar

  公开号：US20060247303A1

  公开（公告）日：2006-11-02

  The present invention relates to substituted 7H-dibenzo[b,g][1,5]dioxocin-5-one-derivatives, to processes for their preparation and to their use in medicaments, in particular as inhibitors of the cholesterol ester transfer protein (CETP) for the treatment and/or prevention of cardiovascular disorders, in particular hypolipoproteinaemia, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias and arteriosclerosis.

  本发明涉及取代的7H-二苯并[b，g][1,5]二氧杂环戊烷-5-酮衍生物，其制备过程以及它们在药物中的应用，特别是作为胆固醇酯转移蛋白（CETP）的抑制剂，用于治疗和/或预防心血管疾病，特别是低脂蛋白血症，脂质代谢异常，高三酰甘油血症，高脂血症和动脉硬化。
• 7-AMINOIMIDAZOTRIAZONES
  申请人：Bayer HealthCare AG

  公开号：EP1504008A1

  公开（公告）日：2005-02-09
• Dibenzodioxocinones—A new class of CETP inhibitors
  作者：David Brückner、Frank-Thorsten Hafner、Volkhart Li、Carsten Schmeck、Joachim Telser、Alexandros Vakalopoulos、Gabriele Wirtz

  DOI：10.1016/j.bmcl.2005.05.073

  日期：2005.8

  Derivatives of the natural product 11-hydroxy-3-[(S)-1-hydroxy-3-methylbutyl]-4-methoxy-9-methyl-5H,7H-dibenzo[b,g][1,5]dioxocin-5-one 1 were studied as novel CETP inhibitors. Compound 2 was identified from HTS as a micromolar inhibitor. The compound suffered from very low stability in plasma. Optimisation by partial synthesis started from 1 and led to low-nanomolar inhibitors with good stability in rat plasma. (c) 2005 Elsevier Ltd. All rights reserved.